The IDEXX-SDMATM test is a non-invasive test being marketed for diagnosing and monitoring chronic kidney disease in cats and dogs. The objective of this study was to determine if the serum concentration SDMA and creatinine increase in cats with meloxicam-induced kidney damage.
Female cats (n=12) were allocated to 2 experimental groups: control group (n=6) and meloxicam group (n=6). Cats in the control and meloxicam groups were treated with saline and meloxicam, respectively. Serum SDMA IDEXXTM and creatinine concentrations were assessed before and after the administration of the treatments. Histopathology was performed on kidneys from all cats.
In the meloxicam group, severe tubular changes were observed in 5 out of 6 cats. Before starting the administration of the treatments, all cats had comparable serum concentrations of creatinine (≤1.6 mg/dL) and SDMA (≤14mg/dL). Unexpectedly, SDMA concentrations rose above the normal reference range only in 3 out of the 5 cats with meloxicam-induced kidney damage. The time required for SDMA and creatinine to surpass the reference concentration was similar for each cat.
This study is the first one reporting the changes in the serum concentration of SDMA in healthy cats that develop NSAID-kidney damage.Results of this study suggest that; (i) the serum concentration of SDMA did not detect kidney tubular damage induced by the repeated administration of meloxicam earlier than creatinine in cats and (ii) clinicians may be unable to detect extensive kidney tubular damage in some cats by using SDMA and creatinine, at least until glomerulus are severely affected.
College of Veterinary Medicine, WSU
Nicolás Villarino obtained the degree in veterinary medicine (2000) in Argentina. In 2006, he completed his first postgraduate program obtaining the degree in Doctor of Veterinary Sciences in Argentina. While in this program, he gained extensive research experience in inflammatory models and anti-inflammatory therapies. In 2012, Dr. Villarino completed a dual Ph. D. / residency program in clinical pharmacology at the University of Tennessee. During this program his work was mainly focused pharmacokinetics of antimicrobials in animals. During the same year, he became American Board Certified in Veterinary Clinical Pharmacology and two years later Dr. Villarino completed a post-doctoral training program working on new strategies to control severe human plasmodium infections. Dr. Villarino has joined the Program in Individualized Medicine (PRIME) at the College of Veterinary Medicine at Washington State University. In collaboration with Drs. Mealey and Court, his research is focused on the discovery of genetic and metabolic biomarkers for individualizing pharmacological interventions for domestic animals.
Friday, June 15
11:30 AM – 11:45 AM
The asset you are trying to access is locked. Please enter your access key to unlock.